NFL Biosciences specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. At the end of 2025, the company has two products in clinical development (NFL-101 and NFL-102) and two products in preclinical development (NFL-201 for the treatment of cannabis addiction and NFL-301 for alcohol addiction).

Employees

Sector

Biotechnology & Medical Research

Calendar

Oct. 22 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-09-14	€0.8200	-2.38%	17,312
26-09-11	€0.8400	-2.33%	47,488
26-09-10	€0.8600	-2.71%	4,518
26-09-09	€0.8840	-0.11%	16,472
26-09-08	€0.8850	-1.01%	8,291

Real-time Euronext Paris

More quotes

Annual profits - Rate of surprise

Company calendar

Market Closed - Euronext Paris 11:55:00 2026-09-14 am EDT			5-day change	1st Jan Change
0.8200 ^EUR	-2.38%		-8.28%	-30.39%

Jul. 28	NFL Biosciences Submits Application For Authorization Of The Phase 2 Tonic Clinical Trial Evaluating NFL-102 In Smoking Cessation	CI
Jul. 07	Nfl Biosciences Presents Three Scientific Communications on Nfl-101 and Nfl-102 At 2026 Srnt-Europe Conference	CI

Market Cap	10.39M 11.99M 9.81M 8.9M 16.69M 1.15B 16.81M 117M 45.13M 583M 45.04M 44.05M 1.85B	P/E 2024	-9.56x	P/E 2025	-4.62x
Enterprise Value	8.77M 10.12M 8.28M 7.51M 14.09M 970M 14.19M 98.86M 38.1M 492M 38.02M 37.18M 1.56B	EV / Sales 2024	370,592x	EV / Sales 2025	70,790x
Free-Float	85.79%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Euronext Paris	ALNFL	Real-time
Deutsche Boerse AG	82F	Delayed
Börse Stuttgart	82F	Delayed

Jul. 28	NFL Biosciences Submits Application For Authorization Of The Phase 2 Tonic Clinical Trial Evaluating NFL-102 In Smoking Cessation	CI
Jul. 07	Nfl Biosciences Presents Three Scientific Communications on Nfl-101 and Nfl-102 At 2026 Srnt-Europe Conference	CI
Jun. 30	NFL Biosciences Successfully Manufactures GMP Clinical Batch Of NFL-102 And Validates Industrial Production Chain	CI
Jun. 30	NFL Biosciences validates industrial-scale production of NFL-102 for smoking cessation
Jun. 01	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation	CI
Jun. 01	NFL Biosciences validates breakthrough in personalized medicine
May. 26	Glimmers of hope for Middle East peace grow brighter
May. 26	NFL Biosciences to File Patent Application for Smoking Cessation Drug-linked Biomarker	MT
May. 25	NFL Biosciences files new patent application
May. 25	NFL Biosciences Files Patent Application Protecting Predictive Efficacy Biomarker Associated With NFL-101	CI
May. 11	NFL Biosciences SA Clarifies Objectives And Evaluation Criteria For Predictive Biomarker Associated With NFL-101	CI
May. 04	NFL Biosciences Presents Work On NFL-102 For Smoking Cessation At International Scientific Conferences	CI
Apr. 15	NFL Biosciences SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI

NFL Biosciences Stock

Stocks

ALNFL

FR0014003XT0

Biotechnology & Medical Research

Valuation: NFL Biosciences

Chart: NFL Biosciences

Latest news: NFL Biosciences

Analysts' recommendations: NFL Biosciences

Press Releases: NFL Biosciences

News in other languages: NFL Biosciences

Quotes and Performance

Price Extremes

Managers and Directors: NFL Biosciences

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

25-10-20	Nfl Biosciences Outlines Its Development Plan for Nfl-101 in Smoking Cessation Following Receipt of Scientific Advice from Several European Agencies and the U.S. Fda	CI
24-10-02	NFL Biosciences: Invest Securities reduces its target
24-07-15	NFL Biosciences: Invest Securities raises its target

Sep. 08	NFL Biosciences to Present Its Personalized Medicine Approach to Smoking Cessation at the 20th Congress of the Société Francophone de Tabacologie	BU
Jul. 28	NFL Biosciences Submits an Application for Authorization of the Phase 2 TONIC Clinical Trial Evaluating NFL-102 in Smoking Cessation	BU
Jul. 07	International Scientific Recognition for NFL Biosciences: 3 Presentations Selected at the 2026 SRNT-Europe Conference, Including an Oral Presentation on NFL-102	BU
Jun. 30	NFL Biosciences Announces the Successful Manufacturing of a GMP Clinical Batch of NFL-102 and Validates Its Industrial Production Chain	BU
Jun. 01	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation	BU

Sep. 08	NFL Biosciences présentera ses travaux sur le biomarqueur de NFL-101 à un Congrès
Sep. 08	NFL Biosciences présentera au 20ème Congrès de la Société Francophone de Tabacologie son approche de médecine personnalisée dans le sevrage tabagique
Jul. 28	NFL Biosciences dépose la demande d'autorisation de l'étude clinique de phase 2 TONIC évaluant NFL-102 dans le sevrage tabagique
Jul. 07	NFL Biosciences : Bilan semestriel du contrat de liquidité
Jul. 07	Reconnaissance scientifique internationale pour NFL Biosciences : 3 présentations retenues au congrès SRNT-Europe 2026, dont une communication orale sur NFL-102

1 day	-2.38%
1 week	-8.28%
Current month	-8.89%
1 month	-1.44%
3 months	-8.89%
6 months	-26.13%
Current year	-30.39%

1 week	0.81	0.89
1 month	0.81	0.94
Current year	0.8	1.85
1 year	0.8	1.85
3 years	0.8	3.28
5 years	0.55	5
10 years	0.55	5

Manager	Title	Age	Since
Bruno Lafont CEO	Chief Executive Officer	-	2024-10-16
Guillaume Audema DFI	Director of Finance/CFO	-	-
Violaine Desort Henin CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Yannick Plétan BRD	Director/Board Member	-	2021-05-18
Ignacio Faus CHM	Chairman	-	2023-02-26
Bruno Lafont CHM	Chairman	-	2024-10-16

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NFL BIOSCIENCES	-2.38%	-8.28%	-39.88%	-71.72%	12.35M
WUXI APPTEC CO., LTD.	+5.04%	+3.27%	+50.62%	+105.43%	66.93B
ARGENX SE	+1.64%	-0.18%	+34.67%	+76.81%	61.97B
INSMED INCORPORATED	-3.18%	-0.78%	-14.14%	+369.82%	28.26B
WUXI BIOLOGICS (CAYMAN) INC.	+4.55%	-0.08%	+34.70%	+17.28%	24.59B
BIONTECH SE	+2.20%	-4.72%	+2.19%	-13.14%	24.3B
GENMAB A/S	+1.15%	-2.26%	+17.56%	-16.53%	19.41B
PHARMAESSENTIA CORPORATION	-7.03%	-9.16%	+161.91%	+303.00%	16.77B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.44%	-1.68%	-5.00%	+541.17%	14.18B
SUMMIT THERAPEUTICS INC.	+4.96%	+4.63%	-2.75%	+864.40%	14B
Average	+1.04%	-4.38%	+23.99%	+217.65%	27.04B
Weighted average by Cap.	+1.99%	-2.84%	+33.25%	+173.46%

	2024	2025
Net sales	46 53.09 43.41 39.38 73.88 5.09K 74.41 518.45 199.78 2.58K 199.39 194.99 8.21K	188 216.96 177.42 160.95 301.93 20.8K 304.12 2.12K 816.48 10.55K 814.9 796.93 33.54K
Net income	-2.08M -2.4M -1.96M -1.78M -3.34M -230M -3.37M -23.45M -9.04M -117M -9.02M -8.82M -371M	-3.32M -3.83M -3.13M -2.84M -5.33M -367M -5.37M -37.4M -14.41M -186M -14.38M -14.06M -592M
Net Debt	-2.07M -2.39M -1.96M -1.77M -3.33M -229M -3.35M -23.36M -9M -116M -8.98M -8.79M -370M	-1.62M -1.87M -1.53M -1.39M -2.6M -179M -2.62M -18.25M -7.03M -90.87M -7.02M -6.86M -289M